Novo Nordisk and Wegovy: The GLP-1 Portfolio in Context

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Wegovy is the Novo Nordisk product most associated with weight management, but it is one piece of a larger GLP-1 portfolio — and seeing the whole lineup clarifies what Wegovy is approved to do. This guide lays out the portfolio, the FDA indications, and how the competitive landscape actually breaks down. Begin at our Education Hub for the wider library.

Where Wegovy fits

Wegovy is semaglutide 2.4 mg, FDA-approved for chronic weight management in 2021. It shares its active ingredient with Ozempic (semaglutide, FDA-approved for type 2 diabetes in 2017) and Rybelsus (oral semaglutide, FDA-approved for type 2 diabetes in 2019). Novo Nordisk also markets Victoza (liraglutide, FDA-approved for type 2 diabetes in 2010 with a 2017 cardiovascular indication) and Saxenda (liraglutide 3 mg, FDA-approved for chronic weight management in 2014). The pipeline includes CagriSema, a cagrilintide-plus-semaglutide combination.

Why Wegovy and Ozempic differ

Both are semaglutide, but Wegovy is approved for chronic weight management while Ozempic is approved for type 2 diabetes. The distinct indications — not different molecules — are what separate them, which is why they are not interchangeable and are prescribed for different purposes.

Novo Nordisk versus Eli Lilly

The two companies dominate the GLP-1 landscape with contrasting strategies. Novo Nordisk emphasizes GLP-1-selective compounds (semaglutide, liraglutide); Eli Lilly markets the only FDA-approved GIP/GLP-1 dual agonist (tirzepatide) plus a GLP-1-selective option (dulaglutide). Head-to-head trials — SURPASS-2 (tirzepatide vs semaglutide 1 mg in type 2 diabetes) and SUSTAIN 7 (semaglutide vs dulaglutide) — inform the picture, though direct weight-management head-to-head data is limited.

Cost positioning

Manufacturer list prices are broadly similar across branded products — typically $800–$1,600 per month at U.S. list as of April 2026. Savings-card programs differ by product, and patient-assistance programs exist at both companies for eligible uninsured or underinsured patients. Compounded alternatives through 503A pharmacies are priced separately.

Shared class safety profile

All FDA-approved GLP-1 receptor agonists and GIP/GLP-1 dual agonists across both manufacturers carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies, and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Common side effects are gastrointestinal; rare serious events include pancreatitis, gallbladder events, and acute kidney injury in the context of dehydration.

The genetics upstream

Whichever product a conversation lands on, the same pathway-level genetics sit underneath. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, and before any protocol the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including variants in TCF7L2, FTO, MC4R that shape baseline GLP-1 and energy-balance biology. It does not predict response to any manufacturer's products.

Reading approvals rather than headlines

Weight-management coverage and headlines change quickly, but FDA-approved indications are the stable reference point underneath the noise. Wegovy's approval for chronic weight management and Ozempic's approval for type 2 diabetes are not interchangeable technicalities — they define what each product is cleared to do and shape how insurers treat them.

Keeping that framing in view helps you interpret both marketing and coverage rules more accurately. A product's brand recognition tells you little about whether a given plan will cover it or whether it fits a particular clinical situation; the indication and the shared class safety profile tell you far more. Anchoring on those durable facts, rather than the shifting headlines around them, is what lets a conversation with a provider stay grounded in what actually matters.

For patients navigating a crowded field, that discipline pays off. Indications, evidence, and the shared class safety profile are the facts that survive changing headlines, and they are the ones worth carrying into a provider conversation. Layered on top of the upstream genetic context, they give you a stable foundation for understanding where any single product actually fits.

None of this replaces a clinical conversation; it prepares you for one. Walking into a provider visit already understanding how Wegovy sits in the portfolio, what its indication means, and which safety considerations apply across the class lets you spend that time on the questions that are specific to you rather than on the basics.

Frequently Asked Questions

What GLP-1 products does Novo Nordisk make?

Novo Nordisk markets Ozempic (semaglutide for type 2 diabetes), Wegovy (semaglutide 2.4 mg for chronic weight management), Rybelsus (oral semaglutide for type 2 diabetes), Victoza (liraglutide for type 2 diabetes), and Saxenda (liraglutide 3 mg for chronic weight management). Each product has a distinct FDA-approved indication.

Is Wegovy the same as Ozempic?

Both contain semaglutide, but they carry different FDA-approved indications: Wegovy for chronic weight management and Ozempic for type 2 diabetes. The molecule is shared; the approvals and intended uses differ, so they are not interchangeable and are prescribed for different clinical purposes.

How do costs compare between the two companies?

Manufacturer list prices are broadly similar — typically $800–$1,600 per month at U.S. list as of April 2026. Savings programs, insurance coverage, and out-of-pocket cost vary more by product, plan, and indication than by manufacturer. Verify current terms at the time of fill.

How does the genetic test relate to these products?

It does not predict response to any manufacturer's products. The Precision Peptide Genetic Test analyzes pathway-level variants in TCF7L2 and FTO, and MC4R that shape baseline GLP-1 and energy-balance biology — the upstream context that applies across both Novo Nordisk and Eli Lilly compounds.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.